Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine

Philip C.S. De Whalley, Matthew D. Snape, Dominic F. Kelly, Carly Banner, Susan Lewis, Linda Diggle, Tessa M. John, Ly Mee Yu, Omar Omar, Astrid Borkowski, Andrew J. Pollard

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Bactericidal antibody induced by immunization of infants with serogroup C Neisseria meningitidis (MenC) vaccines wanes rapidly during childhood. Adolescents are at particular risk from meningococcal disease, therefore they might benefit from a booster dose of vaccine. The duration of serologic response to such a booster in adolescents is unknown. Methods: In a previous study, English schoolchildren, aged 9 to 12 years, who had received a monovalent MenC glycoconjugate vaccine in 1999-2000, were given either a plain polysaccharide vaccine (MenC-PS group, n = 150) or a glycoconjugate vaccine (MenC-CRM group, n = 95) at 13 to 15 years of age. In this follow-up study, serum bactericidal antibody titers and specific immunoglobulin G concentrations were assessed 1 year later. Results were compared with unboosted controls of similar age (control group, n = 298). Results: Compliance with study protocol was achieved for 146 of the MenC-PS group, 92 of the MenC-CRM group, and 293 of the control group. Compared with the control group, both the MenC-PS and MenC-CRM groups had a significantly higher (P < 0.0001) geometric mean serum bactericidal antibody titers 1 year after the booster dose (geometric mean titers for MenC-PS group 3388 [95% confidence interval {CI}: 2460-4665]; MenC-CRM group 4417 [95% CI: 2951-6609]; control group 316 [95% CI: 252-396]). Specific immunoglobulin G concentration also rose and remained elevated 1 year after the booster. Conclusions: A booster dose of MenC vaccine given to adolescents produced a marked rise in bactericidal antibody, which remained elevated 1 year later. Introduction of an adolescent booster of MenC vaccine might provide enhanced long-term population control of the disease.

Original languageEnglish
JournalPediatric Infectious Disease Journal
Volume30
Issue number11
DOIs
Publication statusPublished - 1 Nov 2011
Externally publishedYes

Fingerprint

Serogroup C Neisseria meningitidis
Glycoconjugates
Polysaccharides
Vaccines
Antibodies
Serum
Control Groups
Confidence Intervals
Immunoglobulin G
Population Control
Immunization
Age Groups

Keywords

  • adolescent
  • antibody ersistence
  • booster
  • meningococcus
  • vaccine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine. / De Whalley, Philip C.S.; Snape, Matthew D.; Kelly, Dominic F.; Banner, Carly; Lewis, Susan; Diggle, Linda; John, Tessa M.; Yu, Ly Mee; Omar, Omar; Borkowski, Astrid; Pollard, Andrew J.

In: Pediatric Infectious Disease Journal, Vol. 30, No. 11, 01.11.2011.

Research output: Contribution to journalArticle

De Whalley, Philip C.S. ; Snape, Matthew D. ; Kelly, Dominic F. ; Banner, Carly ; Lewis, Susan ; Diggle, Linda ; John, Tessa M. ; Yu, Ly Mee ; Omar, Omar ; Borkowski, Astrid ; Pollard, Andrew J. / Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine. In: Pediatric Infectious Disease Journal. 2011 ; Vol. 30, No. 11.
@article{3668e5d4087c41c29d4623fa7109777c,
title = "Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine",
abstract = "Background: Bactericidal antibody induced by immunization of infants with serogroup C Neisseria meningitidis (MenC) vaccines wanes rapidly during childhood. Adolescents are at particular risk from meningococcal disease, therefore they might benefit from a booster dose of vaccine. The duration of serologic response to such a booster in adolescents is unknown. Methods: In a previous study, English schoolchildren, aged 9 to 12 years, who had received a monovalent MenC glycoconjugate vaccine in 1999-2000, were given either a plain polysaccharide vaccine (MenC-PS group, n = 150) or a glycoconjugate vaccine (MenC-CRM group, n = 95) at 13 to 15 years of age. In this follow-up study, serum bactericidal antibody titers and specific immunoglobulin G concentrations were assessed 1 year later. Results were compared with unboosted controls of similar age (control group, n = 298). Results: Compliance with study protocol was achieved for 146 of the MenC-PS group, 92 of the MenC-CRM group, and 293 of the control group. Compared with the control group, both the MenC-PS and MenC-CRM groups had a significantly higher (P < 0.0001) geometric mean serum bactericidal antibody titers 1 year after the booster dose (geometric mean titers for MenC-PS group 3388 [95{\%} confidence interval {CI}: 2460-4665]; MenC-CRM group 4417 [95{\%} CI: 2951-6609]; control group 316 [95{\%} CI: 252-396]). Specific immunoglobulin G concentration also rose and remained elevated 1 year after the booster. Conclusions: A booster dose of MenC vaccine given to adolescents produced a marked rise in bactericidal antibody, which remained elevated 1 year later. Introduction of an adolescent booster of MenC vaccine might provide enhanced long-term population control of the disease.",
keywords = "adolescent, antibody ersistence, booster, meningococcus, vaccine",
author = "{De Whalley}, {Philip C.S.} and Snape, {Matthew D.} and Kelly, {Dominic F.} and Carly Banner and Susan Lewis and Linda Diggle and John, {Tessa M.} and Yu, {Ly Mee} and Omar Omar and Astrid Borkowski and Pollard, {Andrew J.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1097/INF.0b013e318224fb14",
language = "English",
volume = "30",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine

AU - De Whalley, Philip C.S.

AU - Snape, Matthew D.

AU - Kelly, Dominic F.

AU - Banner, Carly

AU - Lewis, Susan

AU - Diggle, Linda

AU - John, Tessa M.

AU - Yu, Ly Mee

AU - Omar, Omar

AU - Borkowski, Astrid

AU - Pollard, Andrew J.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Background: Bactericidal antibody induced by immunization of infants with serogroup C Neisseria meningitidis (MenC) vaccines wanes rapidly during childhood. Adolescents are at particular risk from meningococcal disease, therefore they might benefit from a booster dose of vaccine. The duration of serologic response to such a booster in adolescents is unknown. Methods: In a previous study, English schoolchildren, aged 9 to 12 years, who had received a monovalent MenC glycoconjugate vaccine in 1999-2000, were given either a plain polysaccharide vaccine (MenC-PS group, n = 150) or a glycoconjugate vaccine (MenC-CRM group, n = 95) at 13 to 15 years of age. In this follow-up study, serum bactericidal antibody titers and specific immunoglobulin G concentrations were assessed 1 year later. Results were compared with unboosted controls of similar age (control group, n = 298). Results: Compliance with study protocol was achieved for 146 of the MenC-PS group, 92 of the MenC-CRM group, and 293 of the control group. Compared with the control group, both the MenC-PS and MenC-CRM groups had a significantly higher (P < 0.0001) geometric mean serum bactericidal antibody titers 1 year after the booster dose (geometric mean titers for MenC-PS group 3388 [95% confidence interval {CI}: 2460-4665]; MenC-CRM group 4417 [95% CI: 2951-6609]; control group 316 [95% CI: 252-396]). Specific immunoglobulin G concentration also rose and remained elevated 1 year after the booster. Conclusions: A booster dose of MenC vaccine given to adolescents produced a marked rise in bactericidal antibody, which remained elevated 1 year later. Introduction of an adolescent booster of MenC vaccine might provide enhanced long-term population control of the disease.

AB - Background: Bactericidal antibody induced by immunization of infants with serogroup C Neisseria meningitidis (MenC) vaccines wanes rapidly during childhood. Adolescents are at particular risk from meningococcal disease, therefore they might benefit from a booster dose of vaccine. The duration of serologic response to such a booster in adolescents is unknown. Methods: In a previous study, English schoolchildren, aged 9 to 12 years, who had received a monovalent MenC glycoconjugate vaccine in 1999-2000, were given either a plain polysaccharide vaccine (MenC-PS group, n = 150) or a glycoconjugate vaccine (MenC-CRM group, n = 95) at 13 to 15 years of age. In this follow-up study, serum bactericidal antibody titers and specific immunoglobulin G concentrations were assessed 1 year later. Results were compared with unboosted controls of similar age (control group, n = 298). Results: Compliance with study protocol was achieved for 146 of the MenC-PS group, 92 of the MenC-CRM group, and 293 of the control group. Compared with the control group, both the MenC-PS and MenC-CRM groups had a significantly higher (P < 0.0001) geometric mean serum bactericidal antibody titers 1 year after the booster dose (geometric mean titers for MenC-PS group 3388 [95% confidence interval {CI}: 2460-4665]; MenC-CRM group 4417 [95% CI: 2951-6609]; control group 316 [95% CI: 252-396]). Specific immunoglobulin G concentration also rose and remained elevated 1 year after the booster. Conclusions: A booster dose of MenC vaccine given to adolescents produced a marked rise in bactericidal antibody, which remained elevated 1 year later. Introduction of an adolescent booster of MenC vaccine might provide enhanced long-term population control of the disease.

KW - adolescent

KW - antibody ersistence

KW - booster

KW - meningococcus

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=80055005675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055005675&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e318224fb14

DO - 10.1097/INF.0b013e318224fb14

M3 - Article

VL - 30

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 11

ER -